02 January 2022: Clinical Research
Retrospective Study of 573 Patients with Heart Failure Evaluated for Coronary Artery Disease at Toulouse University Center, France
Antoine Deney 1ABCDEF* , Vanessa Nader 12ABCDEF* , Anthony Matta 13ABCDE , Romain Itier 1CDE , Pauline Fournier 1ABCD , Olivier Lairez 1ADF , Nathalie Pizzinat 4ACD , Didier Carrié 1ACD , Frédéric Boal 4ACD , Michel Galinier 1ACD , Oksana Kunduzova 4ACD , Rania Azar 2ACD , Jerome Roncalli 14ABCDEFG*DOI: 10.12659/MSM.934804
Med Sci Monit 2022; 28:e934804
Table 6 Characteristics of ischemic heart failure (IHF) group stratified by type of heart failure.
| CAD-populationN=320 | HFpEFN=50 | HFrEFN=270 | P-value | |
|---|---|---|---|---|
| Age | 70.95±10.404 | 74.04±8.949 | 70.38±10.567 | 0.022 |
| Male sex | 269 (84.06%) | 42 (84.00%) | 227 (84.07%) | 0.990 |
| BMI | 26.28±4.86 | 27.39±5.63 | 26.08±4.69 | 0.081 |
| Atrial fibrillation | 95 (29.69%) | 11 (22.00%) | 84 (31.11%) | 0.195 |
| Chronic kidney disease | 182 (56.87%) | 27 (54.00%) | 155 (57.41%) | 0.479 |
| Dyslipidemia | 106 (33.13%) | 25 (50.00%) | 81 (30.00%) | 0.007 |
| Diabetes | 113 (35.31%) | 19 (38.00%) | 94 (34.81%) | 0.729 |
| Hypertension | 198 (66.9%) | 36 (72.00%) | 162 (60.00%) | 0.123 |
| Smoking | 85 (26.56%) | 8 (16.00%) | 77 (28.52%) | 0.053 |
| Family history | 47 (14.69%) | 7 (14.00%) | 40 (14.81%) | 0.840 |
| Valvopathy | 131 (40.93%) | 17 (34.00%) | 114 (42.22%) | 0.305 |
| RVD | 58 (18.13%) | 3 (6.00%) | 55 (20.37%) | 0.1 |
| TAPSE | 17.29±4.47 | 17.88±2.69 | 17.26±4.55 | 0.706 |
| PAPSE | 41.38±14.01 | 39.67±11.11 | 41.41±14.30 | 0.772 |
| Pacemaker | 26 (8.13%) | 8 (12.00%) | 20 (7.41%) | 0.268 |
| Defibrillator | 26 (8.13%) | 1 (2%) | 25 (9.26%) | 0.096 |
| NYHA | ||||
| 1 | 13 (4.06%) | 0 | 13 (4.81%) | 0.339 |
| 2 | 83 (25.94%) | 13 (26.00%) | 70 (25.93%) | |
| 3 | 87 (27.19%) | 14 (28.00%) | 73 (27.04%) | |
| 4 | 25 (7.81%) | 1 (2.00%) | 24 (8.89%) | |
| Systolic blood pressure | 129.77±23.12 | 139.73±21.452 | 127.95±22.99 | 0.003 |
| Diastolic blood pressure | 74.50±14.09 | 73.83±19.76 | 74.62±14.35 | 0.742 |
| Heart rate | 79.25±20.78) | 74.43±19.21 | 80.13±20.97 | 0.110 |
| Troponin | 169.84±652.32 | 72.15±62.86 | 186.97±705.82 | 0.470 |
| NT-ProBNP | 5889.47±8758.00 | 3724.19±6747.79 | 6135.28±9017.84 | 0.127 |
| β-blockers | 194 (60.63%) | 24 (48.00%) | 170 (62.96%) | 0.047 |
| Diuretics | 191 (59.69%) | 29 (58.00%) | 162 (60.00%) | 0.768 |
| Mineralocorticoids | 55 (17.19%) | 7 (14.00%) | 48 (17.78%) | 0.552 |
| ACE/ARA | 175 (54.69%) | 27 (54.00%) | 148 (54.81%) | 0.915 |
| ARNI | 24 (7.50%) | 0 | 24 (8.89%) | 0.016 |
| Ivabradine | 5 (1.56%) | 0 | 5 (1.85%) | 1 |
| SAPT | 128 (40.00%) | 25 (50.00%) | 103 (38.15%) | 0.189 |
| DAPT | 43 (13.44%) | 7 (14.00%) | 36 (13.33%) | 0.958 |
| DOAC+AVK | 1 (0.31%) | 0 | 1 (0.37%) | 1 |
| AAP+OAC | 30 (9.37%) | 5 (10.00%) | 25 (9.26%) | 0.677 |
| β-blockers | 267 (83.43%) | 32 (64.00%) | 235 (87.04%) | |
| Diuretics | 245 (76.56%) | 37 (74.00%) | 208 (77.04%) | 0.514 |
| Mineralocorticoids | 117 (36.56%) | 10 (20.00%) | 107 (39.63%) | 0.007 |
| ACE/ARA | 182 (56.87%) | 37 (74.00%) | 145 (53.70%) | 0.011 |
| ARNI | 66 (20.62%) | 1 (2.00%) | 65 (24.07%) | |
| Ivabradine | 11 (3.43%) | 1 (2.00%) | 10 (3.70%) | 1 |
| SAPT | 79 (24.69%) | 22 (44.00%) | 57 (21.11%) | 0.001 |
| DAPT | 201 (62.81%) | 27 (54.00%) | 174 (64.44%) | 0.115 |
| DOAC+AVK | 111 (34.69%) | 15 (30.00%) | 96 (35.55%) | 0.398 |
| AAP+OAC | 77 (24.06%) | 9 (18.00%) | 68 (25.18%) | 0.281 |
| BMI – body mass index; APT – single anti-platelet therapy; DAPT – dual anti-platelet therapy; DOAC – direct oral anti-coagulant; AP+OAC – anti-platelet +oral anti-coagulant. | ||||